Department of Clinical Pathology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong, China.
Department of Paediatrics and Adolescent Medicine, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong, China.
Genes (Basel). 2023 Nov 13;14(11):2071. doi: 10.3390/genes14112071.
Familial hypercholesterolemia (FH) is a prevalent but often underdiagnosed monogenic disorder affecting lipoprotein metabolism, and genetic testing for FH has not been widely conducted in Asia in the past. In this cross-sectional study of 31 probands (19 adults and 12 children) and an addition of 15 individuals (12 adults and 3 children), who underwent genetic testing and cascade screening for FH, respectively, during the period between February 2015 and July 2023, we identified a total of 25 distinct variants in 71.0% unrelated probands. Among the adult proband cohort, a higher proportion of genetically confirmed cases exhibited a positive family history of premature cardiovascular disease. Treatment intensity required to achieve an approximate 50% reduction in pretreatment low-density lipoprotein cholesterol (LDL-C) exhibited potentially better diagnostic performance compared to pretreatment LDL-C levels, Dutch Lipid Clinic Network Diagnostic Criteria (DLCNC) score, and modified DLCNC score. Adult individuals identified through cascade screening demonstrated less severe phenotypes, and fewer of them met previously proposed local criteria for FH genetic testing compared to the probands, indicating that cascade screening played a crucial role in the early detection of new cases that might otherwise have gone undiagnosed. These findings underscore the significance of genetic testing and cascade screening in the accurate identification and management of FH cases.
家族性高胆固醇血症(FH)是一种常见但常被漏诊的单基因疾病,影响脂蛋白代谢,过去在亚洲,FH 的基因检测并未广泛开展。在这项 2015 年 2 月至 2023 年 7 月期间进行的横断面研究中,我们对 31 名先证者(19 名成人和 12 名儿童)和另外 15 名分别接受 FH 基因检测和级联筛查的个体进行了研究,共在 71.0%的非相关先证者中发现了 25 个不同的变异。在成年先证者队列中,具有阳性早发性心血管疾病家族史的遗传确诊病例比例更高。与治疗前 LDL-C 水平、荷兰血脂临床网络诊断标准(DLCNC)评分和改良 DLCNC 评分相比,达到治疗前 LDL-C 降低 50%所需的治疗强度具有更好的诊断性能。通过级联筛查发现的成年个体表现出的表型较轻,与先证者相比,他们中符合先前提出的 FH 基因检测局部标准的比例较低,这表明级联筛查在早期发现新病例方面发挥了关键作用,否则这些新病例可能会被漏诊。这些发现强调了基因检测和级联筛查在 FH 病例的准确识别和管理中的重要性。